Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019

ABSTRACT: BACKGROUND: Recent patent losses for antiretroviral drugs (ARV) have led to the debate of cost-saving through the replacement of patented drugs with generic drugs. The split of recommended single-tablet regimens (STR) into their single substance partners is one of the considerations mentio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lottes, Matthäus, Bremer, Viviane, Prugger, Christof, Kollan, Christian, Schmidt, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756633/
https://www.ncbi.nlm.nih.gov/pubmed/35027062
http://dx.doi.org/10.1186/s12913-021-07390-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756633/
https://www.ncbi.nlm.nih.gov/pubmed/35027062
http://dx.doi.org/10.1186/s12913-021-07390-4

Ejemplares similares